Evommune
Yahoo Finance • 11 days ago
Evommune Stock Sees RS Rating Rise To 91
On Wednesday, Evommune stock earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 91. Looking For The Best Stocks To Buy And Watch? Start Here This unique rating measures market leadership by showing how a stock's... Full story
Yahoo Finance • 11 days ago
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Truist upgraded Block (XYZ) to Buy fro... Full story
Yahoo Finance • 19 days ago
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade
Many clinical-stage biotech stocks have the potential to surge by more than 1,000% if they successfully make the transition to the commercial stage with approved and well-received therapies. But small-cap biotechs are also among the riski... Full story
Yahoo Finance • 23 days ago
Evommune, Inc Loss At -$28.27 Mln In Q4
(RTTNews) - Evommune, Inc (EVMN) reported Loss for fourth quarter of -$28.27 million The company's earnings totaled -$28.27 million, or -$1.43 per share. This compares with -$20.73 million, or -$13.58 per share, last year. Evommune, Inc... Full story
Yahoo Finance • 2 months ago
Evommune surges on mid-stage trial win for eczema therapy
[$10 Banknote Stacking, Green Up Arrow Rise] spawns Evommune (EVMN [https://seekingalpha.com/symbol/EVMN]) added more than ~50% in early trading on Tuesday after the biotech announced a mid-stage trial win for EVO301, its experimental the... Full story
